| Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB (NCT07672405) | Global Alliance for TB Drug Development | 2026-07-09 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis (NCT06058299) | Global Alliance for TB Drug Development | 2023-10-31 |
| A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults (NCT05526911) | Global Alliance for TB Drug Development | 2022-06-30 |
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis (NCT04179500) | Global Alliance for TB Drug Development | 2021-09-16 |
| Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects (NCT04865536) | Global Alliance for TB Drug Development | 2021-02-03 |
| Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults (NCT04890535) | Global Alliance for TB Drug Development | 2020-12-01 |
| Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults (NCT04493671) | Global Alliance for TB Drug Development | 2020-06-08 |
| Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid (NCT04309656) | Global Alliance for TB Drug Development | 2020-01-14 |
| A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults (NCT03758612) | Global Alliance for TB Drug Development | 2019-01-16 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients (NCT03338621) | Global Alliance for TB Drug Development | 2018-07-30 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis (NCT03086486) | Global Alliance for TB Drug Development | 2017-11-21 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid (NCT03199313) | Global Alliance for TB Drug Development | 2017-09-26 |